<DOC>
	<DOCNO>NCT01453764</DOCNO>
	<brief_summary>The intent clinical study answer question : 1 . Is propose treatment safe 2 . Is treatment effective improve disease pathology patient Multiple Sclerosis clinical outcome ?</brief_summary>
	<brief_title>Study Assess Safety Effects Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis</brief_title>
	<detailed_description>This open-label , non-randomized multi-center patient sponsor study Adipose-Derived Stromal Cells ( ASC ) implantation perform intrathecally intravenously . ASCs derive patient 's adipose-derived tissue . Liposuction use local anesthesia syringe collection perform collect adipose tissue specimen subsequent process isolate stem cell .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Autoimmune Diseases Nervous System</mesh_term>
	<criteria>Males Females Age 18 80 year . Duration disease : &gt; 5 year Failure respond intolerance currently available Multiple Sclerosis ( MS ) immunomodulatory treatment ( ie interferon , Copaxone , immunosuppression ) : lack response treatment determined/defined either increase ( deterioration ) least one degree Expanded Disability Status Scale ( EDSS ) score last year appearance least two major relapse MS period time ( treatment ) intolerance agent . Up date age gender appropriate cancer screen per American Cancer Society . Females pregnant nursing female childbearing potential unwilling maintain contraceptive therapy duration study Life expectancy &lt; 6 month due concomitant illness . Exposure investigational drug procedure within 1 month prior study entry enrol concurrent study may confound result study . Active infectious disease . For patient test positive , expert consult patient eligibility base patient 's infectious status Any illness , Investigator 's judgment , interfere patient 's ability comply protocol , compromise patient safety , interfere interpretation study result Patients chronic immunosuppressive transplant therapy Systolic blood pressure ( supine ) â‰¤90 mmHg ; Resting heart rate &gt; 100 bpm ; Active clinical infection . Cerebrovascular accident within 6 month prior study entry Known drug alcohol dependence factor interfere study conduct interpretation result opinion investigator suitable participate . History cancer ( nonmelanoma skin cancer insitu cervical cancer ) last five year . Unwilling and/or able give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>